DMK Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases   2 Products   5 Trials   105 News 


12»
  • ||||||||||  epinephrine / Generic mfg.
    Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) -  Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_1180;    
    No abstract available effy (epinephrine nasal spray) was more stable than injection products and remained within shelf-life specifications for potency even after 3-months under extreme temperature conditions (50
  • ||||||||||  Kloxxado (naloxone intranasal spray) / Hikma, Zimhi (naloxone injection) / DMK Pharma, US WorldMeds
    Journal:  Nalmefene nasal spray (Opvee) for reversal of opioid overdose. (Pubmed Central) -  Oct 24, 2023   
    Overall, the fishmeal in common carp feed could be substituted up to 50% by CPC without negative influence on growth, feed utilization, and or intestinal health. No abstract available
  • ||||||||||  Journal:  Drugs for opioid use disorder. (Pubmed Central) -  Sep 7, 2023   
    AVN hospitalizations were more likely to be younger and of the Black race. No abstract available
  • ||||||||||  Symjepi (epinephrine) / Adamis, US WorldMeds, epinephrine / Generic mfg.
    Journal:  Symjepi Epinephrine Injection Device Deconstruction and Residual Medication Retrieval in an Austere Environment. (Pubmed Central) -  Mar 21, 2023   
    Previous articles have demonstrated the deconstruction of spring-loaded epinephrine autoinjectors to extract additional medication doses. This article provides instruction and videography, outlining the process of deconstructing and obtaining additional doses of epinephrine from the Symjepi prefilled syringe.
  • ||||||||||  tempol (MBM-02) / DMK Pharma, Matrix Biomed
    Trial termination:  Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (clinicaltrials.gov) -  Dec 6, 2022   
    P2/3,  N=248, Terminated, 
    The findings suggest that the optimum substitution rate of dietary fishmeal by CPC for rainbow trout should be less than 75%. Recruiting --> Terminated; Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo
  • ||||||||||  Kloxxado (naloxone intranasal spray) / Hikma, Zimhi (naloxone injection) / Adamis, US WorldMeds
    Journal:  Nalmefene returns for reversal of opioid overdose. (Pubmed Central) -  Sep 20, 2022   
    Recruiting --> Terminated; Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo No abstract available
  • ||||||||||  Zimhi (naloxone injection) / Adamis, US WorldMeds
    Journal:  New Naloxone Concentration Treats Opioid Overdose. (Pubmed Central) -  Feb 10, 2022   
    Zimhi is a single-dose prefilled syringe containing 5 mg/0.5 mL of naloxone. Zimhi is administered subcutaneously or intramuscularly.Nurses should educate patients receiving opioids and their families on how to use Zimhi or other prescribed naloxone products.
  • ||||||||||  Neffy (epinephrine) / ARS Pharma, Neurelis
    Neffy Human Factor Findings () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1736;    
    The intended users demonstrated that they were able to safely and successfully use the Aptar Unit Dose System during an emergency scenario. This included dosing themselves or a simulated patient.
  • ||||||||||  epinephrine / Generic mfg.
    Clinical, Review, Journal:  Anaphylaxis: Access to Epinephrine in Outpatient Setting. (Pubmed Central) -  Jan 5, 2022   
    Advantages, disadvantages, and costs of available products are discussed and the socioeconomic factors impacting access to EAIs described. EAIs designed for infants also are discussed.
  • ||||||||||  tempol (MBM-02) / DMK Pharma, Matrix Biomed
    Enrollment open, Trial completion date, Trial primary completion date:  Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (clinicaltrials.gov) -  Aug 26, 2021   
    P2/3,  N=248, Recruiting, 
    EAIs designed for infants also are discussed. Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  tempol (MBM-02) / DMK Pharma, Matrix Biomed
    Trial initiation date:  Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (clinicaltrials.gov) -  Aug 18, 2021   
    P2/3,  N=248, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Initiation date: May 2021 --> Aug 2021
  • ||||||||||  Zimhi (naloxone injection) / Adamis, US WorldMeds
    Journal:  The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. (Pubmed Central) -  Jan 6, 2021   
    To address this need, a higher dose of NLX has been investigated in a 5 mg IM formulation called ZIMHI but, while the effects of intravenous (IV) and IN administration of NLX on the opioid mu receptor occupancy (RO) have been studied, comparatively little is known about RO for IM administration of NLX...Plasma levels were 4.6 ng/mL, 16.8 ng/mL, and 43.4 ng/mL for the three IM doses, and a significant correlation between percent RO and plasma NLX level was observed (r = 0.80). These results suggest that higher doses of IM NLX result in higher mu RO and could be useful in combating overdoses resulting from potent synthetic opioids.
  • ||||||||||  Zimhi (naloxone injection) / Adamis, US WorldMeds
    NDA:  $ADMP Resubmits ZIMHI NDA (Twitter) -  May 18, 2020